The average one-year price target for Ambrx Biopharma (NYSE:AMAM) has been revised to 25.79 / share. This is an increase of 8.17% from the prior estimate of 23.84 dated October 4, 2023. The price ...
Fintel reports that on October 23, 2023, Cantor Fitzgerald reiterated coverage of Ambrx Biopharma (NYSE:AMAM) with a Overweight recommendation. As of October 5, 2023, the average one-year price target ...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Ambrx Biopharma, Inc. (NASDAQ: AMAM) to Johnson & Johnson for $28.00 per share in cash is ...
Ambrx Biopharma is a biotech company with an advanced approach to antibody-drug conjugates (ADCs) for oncology. Their proprietary platform for expanded genetic code technology creates ADCs for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results